Study finds Pfizer’s RSV vaccine not tied to higher risk of pre-term births, ET HealthWorld

[Pelican Press 0]

This is the hidden content, please

• Sign In
• or
• Sign Up

Study finds Pfizer’s RSV vaccine not tied to higher risk of pre-term births, ET HealthWorld

By Christy Santhosh

London: Pfizer’s respiratory syncytial virus (RSV) vaccine for pregnant women was not tied to a higher risk of pre-term or early births, according to a study published on Monday that analysed real-world use of the shots.

The vaccine Abrysvo was approved by the U.S. Food and ***** Administration last year for women in their second or third trimesters of pregnancy to prevent infections tied to RSV in ******* in the first six months after birth.

However, some experts had raised concerns over a higher number of pre-term births among participants taking the Pfizer shot compared to those who received a placebo in the company’s clinical trial.

Researchers from Weill Cornell Medical College in New York conducted the retrospective study in women who were 24 to 36 weeks into pregnancy, and found no significant statistical difference between the vaccinated women’s pre-term birth rate of 5.9 per cent compared with unvaccinated women’s 6.7 per cent .

Health regulators however recommended a narrower gestational window, said Annette Regan, from the University of San Francisco’s School of Nursing and Health Professions, in an editorial accompanying the study.

“Despite the need for further research and surveillance, results from this study should offer initial reassurance to regulators, policymakers, health care professionals, and pregnant patients,” Regan wrote in the article published in JAMA.

In most of the continental U.S., the Centers for ******** Control and Prevention (CDC) and the Advisory Committee on Immunisation Practices (ACIP) recommend the vaccine for women who are 32 to 36 weeks pregnant between September and January.

The study analysed electronic health records of women across two New York City hospitals who gave birth between September last year to late January.

RSV leads to the hospitalisation of about 58,000 to 80,000 children younger than 5 years annually.

Pfizer’s vaccine is the only maternal RSV shot approved in the US. The vaccine, along with rivals by GSK and Moderna, is also approved for older adults. (Reporting by Christy Santhosh in Bengaluru; Editing by Vijay Kishore)

• Published On Jul 9, 2024 at 06:49 AM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

• Get Realtime updates
• Save your favourite articles

Scan to download App

This is the hidden content, please

• Sign In
• or
• Sign Up

#Study #finds #Pfizers #RSV #vaccine #tied #higher #risk #preterm #births #HealthWorld

This is the hidden content, please

• Sign In
• or
• Sign Up

This is the hidden content, please

• Sign In
• or
• Sign Up